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Abstract Cardiovascular and metabolic disorders, such as
hypertension, insulin resistance, dyslipidemia or obesity are
linked with chronic low-grade inflammation and dysregu-
lation of the renin–angiotensin system (RAS). Consequently,
RAS inhibition by ACE inhibitors or angiotensin AT1
receptor (AT1R) blockers is the evidence-based standard for
cardiovascular risk reduction in high-risk patients, including
diabetics with albuminuria. In addition, RAS inhibition
reduces the new onset of diabetes mellitus. Yet, the high and
increasing prevalence of metabolic disorders, and the high
residual risk even in properly treated patients, calls for
additional means of pharmacological intervention. In the
past decade, the stimulation of the angiotensin AT2 receptor
(AT2R) has been shown to reduce inflammation, improve
cardiac and vascular remodeling, enhance insulin sensitivity
and increase adiponectin production. Therefore, a concept of
dual AT1R/AT2R modulation emerges as a putative means
for risk reduction in cardio-metabolic diseases. The
approach employing simultaneous RAS blockade (AT1R)
and RAS stimulation (AT2R) is distinct from previous
attempts of double intervention in the RAS by dual blockade.
Dual blockade abolishes the AT1R-linked RAS almost
completely with subsequent risk of hypotension and
hypotension-related events, i.e. syncope or renal dysfunc-
tion. Such complications might be especially prominent in
patients with renal impairment or patients with isolated
systolic hypertension and normal-to-low diastolic blood
pressure values. In contrast to dual RASblockade, the add-on
of AT2R stimulation does not exert significant blood pres-
sure effects, but it may complement and enhance the anti-
inflammatory and antifibrotic/de-stiffening effects of the
AT1R blockade and improve the metabolic profile. Further
studies will have to investigate these putative effects in
particular for settings in which blood pressure reduction is
not primarily desired.
Key Points
The combination of simultaneous RAS blockade
(AT1R) and RAS stimulation (AT2R) represents a
novel promising therapeutic concept, which is distinct
from previous attempts of double intervention in the
RAS by dual blockade.
The add-on of AT2R stimulation complements and
augments the anti-inflammatory and anti-fibrotic effects
of the AT1R blockade.
This combined intervention may address the need for
further risk reduction in patients with well-controlled
blood pressure or where further blood pressure
reduction is not desired, such as in patients with
isolated systolic hypertension, with renal dysfunction or
in the elderly.
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1 Introduction
Cardiovascular mortality remains high world-wide. In Eur-
ope, cardiovascular events remain a major cause of prema-
ture deaths, being responsible for 42 % of all deaths in
women and for 38 %of all deaths inmen aged\75 years [1].
Cardiovascular morbidity and mortality are strongly deter-
mined by the presence ofmetabolic alterations such as different
pro-thrombotic states, dyslipidemia, obesity and insulin resis-
tance (with or without its overt clinical manifestation), which
are clinically grouped in the metabolic syndrome. The cardio-
metabolic syndrome, depending on the definition, usually fea-
tures at least three of the following dysregulations: obesity (or
central obesity), dyslipidemia [hypertriglyceridemia or low
high-density lipoprotein (HDL) levels], hypertension or
impaired glucosemetabolism (impaired fastingglucose, insulin
resistance, hyperinsulinemia or diabetes mellitus), while the
World Health Organization adds microalbuminuria as a crite-
rion as well [2]. Despite the advances in treatment and pre-
vention of cardiovascular diseases, the continuous rise of
metabolic disorders andabnormalitiesmight render thefight for
cardiovascular mortality reduction ineffective. The prevalence
of overweight and obesity is rising in both developing and
developed countries,with 300million people being obese and 1
billion being overweight world-wide [3]. In the overweight and
obese population there is around 40 %prevalence of some type
of altered glucose metabolism [4].
Cardiac and metabolic dysregulations represent two sides
of the cardio-metabolic coin and are interlinked in both
directions. In hypertension, vasoconstriction or vascular rar-
efication was hypothesized to reduce glucose uptake and thus
contribute to hyperglycemia per se [5]. The consequences are
hyperinsulinemia followed by insulin resistance. On the other
hand, there are severalmechanisms bywhich impaired insulin
sensitivity contributes to the development of cardiovascular
pathologies. Insulin resistance blunts the vasodilator effects of
insulin, and chronic hyperinsulinemia increases sympathetic
nervous activity, reduces natriuresis, promotes vascular
smooth muscle growth, endothelial dysfunction and hyper-
triglyceridemiawith subsequent atherosclerosis, hypertension
and vascular events such as myocardial infarction, stroke or
peripheral arterial occlusion disease [6].
2 Behind the Scenes: Pathophysiological
Considerations
2.1 Inflammation in Cardio-Metabolic Diseases
Below the surface of the overt cardio-metabolic presenta-
tions, there is a complex dysregulation of extracellular and
intracellular signaling pathways with chronic low-grade
inflammation at its core. This ‘‘tonic’’ inflammation is,
besides insulin resistance, now recognized as a main etio-
logical factor of obesity-related metabolic disorders [7, 8].
The adipose tissue is on one hand, the target of the
inflammatory process; on the other hand, it can also act as
its important modulator. Clinically, the blood levels of pro-
inflammatory cytokines such as C-reactive protein or
interleukin-6 (IL-6) are not only correlated with excess
adipose mass [9, 10], but they also decrease along with
weight loss [11]. The levels of pro-inflammatory and anti-
inflammatory cytokines depend on the number of adipo-
cytes and even more on the secretory profile of the adipose
tissue. In the adipose tissue of healthy, lean subjects, CD4?
Treg cells prevail, producing type 2 T-helper cell (Th2) anti-
inflammatory cytokines such as the IL-4 and IL-13 and
thereby stimulating the differentiation of the residing
macrophages towards the alternatively activated M2
(F4/80?, CD11b?) CD11c- phenotype [12]. This pheno-
type is characterized by IL-10 production that stimulates
the adipocytes to adiponectin production and enhances
insulin sensitivity. Adiponectin inhibits the nuclear factor
(NF)-jB pathway as well as tumor necrosis factor (TNF)-a
signaling and promotes the expression of the peroxisome
proliferator-activated receptor (PPAR)-c co-activator in
macrophages, further promoting their M2 phenotype [13].
Adiponectin via 50 adenosine monophosphate-activated
protein kinase (AMPK) and subsequent desensitization of
the toll-like receptor (TLR) signaling exhibits anti-
inflammatory effects and through the endothelial NO-
synthase pathway also cardio-protective effects [14].
High concentrations of saturated free fatty acids via
TLR-4, advanced-glycation end-products, or Th1 type
signals [such as interferon-gamma (INF-c)] secreted by
CD8? T cells down-regulate PPAR-c in the macro-
phages and stimulate their differentiation towards the
classically activated M1 (F4/80?, CD11b?) CD11c?
phenotype [15, 16]. These macrophages produce pro-
inflammatory molecules such as TNF-a, IL-6 and the
major chemoattractant protein (MCP)-1. Especially
MCP-1 via the chemokine receptor type 2 (CCR2)
attracts further classically activated macrophages into
the adipose tissue thereby increasing their absolute
number [17]. Under these conditions, the pro-inflamma-
tory molecules are also generated by the adipocytes,
which also produce leptin. Although leptin improves
insulin sensitivity and attenuates hyperlipidemia, it shifts
macrophage differentiation towards the M1 phenotype,
promotes TNF-a and IL-6 production [18, 19] and is
thus considered a pro-inflammatory adipokine [14].
Moreover, due to the development of leptin resistance,
the beneficial effects of leptin are blunted, despite the
high leptin levels in subjects with increased adipose
mass [20].
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In cells, the pro-inflammatory cytokines release the
repression of the nuclear receptor corepressor and subse-
quently also NF-jB, c-Jun N-terminal kinase (JNK) and
phosphoinositide 3-kinase (PI3K) pathways. In macro-
phages and adipocytes, these pathways lead to the trans-
activation of overlapping sets of pro-inflammatory
molecules [21, 22] and promote cellular insulin resistance
as well as leptin secretion in adipocytes. In both macro-
phages and adipocytes, the loss of nuclear receptor core-
pressor activity can be prevented by PPAR-c activation
(e.g. by thiazolidinediones) resulting in reduced inflam-
mation and improved insulin sensitivity. As insulin resis-
tance evolves, the adipose tissue undergoes adipocyte
hypertrophy and infiltration by inflammatory cells [7].
2.2 Renin–Angiotensin-System Activation
in Cardio-Metabolic Diseases
The components of the local renin–angiotensin system
(RAS), such as angiotensin I (Ang I), angiotensin-converting
enzyme (ACE), angiotensin II (Ang II), angiotensin AT1
receptor (AT1R), angiotensin AT2 receptor (AT2R) as well
as alternative enzymes such as cathepsin and chymase, are
abundantly expressed in adipocytes and adipose tissue of
various organs [23, 24]. Overfeeding in rodents results in
increased angiotensinogen formation and increased local
Ang II levels, alterations which were observed in human
hypertensive obese patients as well [25].
Increased circulatory or local RAS activity is clearly
associated with a variety of pathophysiologic processes,
including blood pressure elevation, vasoconstriction, vas-
cular and cardiac remodeling, and renal fibrosis [26].
Moreover, there is a distinct pathophysiological connection
linking increased RAS activity and the metabolic
alterations.
In addition to the hemodynamic link between the
vasoconstrictive effects of Ang II and insulin resistance,
Ang II opposes the effects of insulin on glucose metabo-
lism in the liver and inhibits glycogen synthetase thereby
contributing to insulin resistance [6]. Stimulation of AT1R
by Ang II engenders vasoconstriction and hypokalemia,
both impairing insulin sensitivity [5, 27]. AT1R activation
also inhibits the glucose transporter type 4 (GLUT4) in
skeletal muscle and thus reduces insulin sensitivity [28].
Similar effects might be attributed to ACE activity due to
increased degradation of bradykinin [29]. Ang II further
increases lipogenesis and triacylglyceride content in the
adipocytes by increasing fatty acid synthase and glycerol-
3-phosphate dehydrogenase [30–32]. Stimulation of the
AT1R can also block adipogenesis and adipocyte differ-
entiation thereby reducing insulin sensitivity [33].
Even of higher importance might be the modulatory
effects of RAS on inflammatory activity. As described
above, chronic inflammation plays a key role in the
pathophysiology of the metabolic syndrome. The pro-
inflammatory activity of Ang II via its AT1R is well rec-
ognized [34]. Among others, AT1R activation stimulates
NF-jB, IL-6 and MCP-1 upregulation [35]. In obese mice
on high-fat diet, AT1R blockade or AT1R-knock out
(AT1R-KO) reduced renal macrophage infiltration,
induced a shift from the deleterious M1 to the M2 mac-
rophage phenotype, and prevented renal injury. Finally,
AT1R-KO mice displayed lower body fat and cholesterol
levels compared to their wild-type controls [36].
3 RAS Modulation in Cardio-Metabolic Disease
3.1 Angiotensin AT1 Receptor Blockers
From a clinical point of view, there is a large body of
evidence for the reduction of cardiovascular morbidity and
mortality by RAS inhibition, in particular in heart failure,
hypertensive, diabetic, or generally, in high-risk patients.
Large clinical trials have been performed with ACE inhi-
bitors, for example, SOLVD [37], CAPP [38] STOP-2 [39]
or HOPE [40] and AT1R blockers (ARBs), for example,
CHARM [41], LIFE [42], VALUE [43] or ONTARGET
[44].
The cardio-protective effects of RAS blockade observed
in these and other trials are consistent with the effects of
RAS blockade in subgroups of diabetic patients. In the
HOPE trial, the ACE inhibitor ramipril achieved numeri-
cally an even higher relative reduction of the primary end-
point (cardiovascular death, myocardial infarction or
stroke) in the diabetic compared to the non-diabetic sub-
population [40]. Similarly, the ARB telmisartan was non-
inferior compared to ramipril with regard to the reduction
of the composite of cardiovascular death, myocardial
infarction and stroke with/without hospitalization (primary
and secondary efficacy outcomes) in the subgroup of dia-
betic patients in the ONTARGET trial [44]. Moreover ACE
inhibitors and ARBs were not only shown to reduce car-
diovascular events in diabetics, but also to reduce the new
onset of diabetes [40, 41, 43, 45, 46]. In addition, there are
several smaller trials conducted specifically in diabetic
patients that have demonstrated the efficacy of ACE inhi-
bitors and ARBs on various surrogate end-points, most
notably albuminuria. The benefit was seen in particular in
patients with proteinuria [47–52].
Yet, despite these successful trials providing new
options for cardio-protection, the high and increasing
prevalence of metabolic disorders calls for further reduc-
tion of the cardiovascular risk. For example the RENAAL
study showed that even the appropriately treated diabetic
patients were still at high cardiovascular and renal risk,
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which could be predicted by the residual albuminuria after
RAS blockade [53, 54].
One of the approaches to address this need was the
development of ARBs with enhanced PPAR-c activity
[55]. Some data indicate that the activation of PPARs
might contribute to the beneficial effects of certain ARBs,
such as telmisartan and irbesartan or the losartan metabo-
lite EXP3179 [56–60]. It was demonstrated, that chronic
treatment with losartan [61] or with high-dose
(160 mg/day) telmisartan [62] are able to activate PPAR-c
in circulating monocytes of patients with hypertension and
metabolic syndrome, respectively. The activation of
PPAR-c, on one hand, exerts lipogenic effects, but on the
other hand it stimulates adiponectin production along with
its insulin-sensitizing effect [63]. A partial PPAR-c ago-
nism might play a positive role, especially in the context of
AT1R blockade, which (via NF-jB inhibition) prevents
PPAR-c down-regulation [64]. However, antidiabetic
actions were also observed under ARB treatment with low
PPAR-c activating potential such as valsartan in both
preclinical [28] and clinical [43] settings. Thus, the extent
of the contribution of PPAR-c activating properties of the
individual ARBs to their clinical antidiabetic outcomes has
not been clearly defined [65]. The development of the
previously reported metabolically targeted ARBs with
PPAR-c activity, such as K-868 or PF-03838135 did not
advance to a clinical phase and no novel data have been
reported for these agents [66]. Another putative approach
to augment the cardio-protective actions of the ARBs is to
complement the AT1R blockade with the activation of the
‘‘protective RAS’’, i.e. by AT2R stimulation.
3.2 Angiotensin AT2 Receptor Agonists
While the current therapeutic strategies aim to prevent an
undesired activation of the AT1R, stimulation of the AT2R
might provide a mean to oppose many of the AT1R-
mediated actions [26, 67, 68]. There is accumulating evi-
dence for the cardio-protective action of the AT2R, which
is based not only on indirect evidence, but also on the
investigation of the effects of a direct AT2R stimulation.
Treatment with the first non-peptide highly selective AT2R
agonist, compound 21, prevented or reverted associated
vascular remodeling in large and middle-sized arteries in
either L-NG-Nitroarginine methyl ester (L-NAME) or
spontaneously hypertensive rats (SHR) [69, 70]. Com-
pound 21 also significantly reduced the ischemic area after
middle cerebral artery occlusion in rats, along with anti-
oxidant and anti-inflammatory effects (such as MCP-1 and
TNF-a down-regulation) [71], and in rats with permanent
coronary artery ligation it improved cardiac function and
myocardial architecture early [72] and later after myocar-
dial infarction [73]. Notably, the cardio-protective effects
of AT2R stimulation were not associated with a reduction
in blood pressure in these or other experiments when
compound 21 was administered peripherally. Compound
21 is under physiological situation not able to cross the
blood–brain barrier. However, when compound 21 was
administered intracerebroventricularly it reduced blood
pressure and exerted sympatholytic action (improved
baroreflex sensitivity) in Wistar Kyoto rats and SHR. These
effects were not affected by AT1R blockade, but were
sensitive to NO-synthase blockade [74]. A similar sympa-
tholytic action was observed after central AT2R stimula-
tion in rats with ligation-induced heart failure [75].
The putative mechanisms behind the beneficial effects
of AT2R stimulation include the activation of the
NO/cyclic guanosine monophosphate (cGMP) pathway
[76], down-regulation and inhibition of mitogen-activated
protein kinases (MAPKs) by protein phosphatases [77, 78],
or direct disruption of AT1R function by AT1R–AT2R
heterodimerization [79]. With regard to cardio-metabolic
disease, the anti-inflammatory effects of AT2R stimulation
appear to be the most relevant. These include the inhibition
of NF-jB activity as a result of 11,12-epoxyeicosatrienoic
acid epoxidation [80], augmented IL-10 production and
T-cell differentiation to the Treg phenotype [81]. Indeed,
the stimulation of the AT2R dose-dependently attenuated
TLR-4 lipopolysaccharide (LPS)-induced TNF-a and IL-6
production but it increased IL-10 production via sustained
selective extracellular-signal-regulated kinase 1/2 (ERK1/
2) phosphorylation [82]. Similar anti-inflammatory effects
were observed in human monocytic cells [83] or in high-fat
diet-induced vascular inflammation [84].
Concerning AT1R–AT2R interaction, it has to be noted
that it might not only take place on the cell membrane by
heterodimerization, as previously reported [79], but it
might be more related to a negative cytoplasmatic cross-
talk [85]. Moreover, the angiotensin receptor function
might be modulated by receptor-associated proteins such as
AT1 receptor-associated protein (ATRAP), AT1 receptor
associated protein 1 (ARAP1) for the AT1R and AT2
receptor interacting protein (ATIP) or AT2 receptor bind-
ing protein of 50 kDa for the AT2R (the topic is discussed
extensively elsewhere [86]).
There are several experimental data confirming the
beneficial effects of AT2R stimulation in vivo in animal
models of metabolic disorders. In type 2 diabetic KKAy
mice, compound 21 improved insulin sensitivity, increased
adiponectin and reduced TNF-a levels, while protecting the
pancreatic b-cells. These effects resulted in reduced body
weight and fat mass within two weeks of treatment.
Interestingly, the beneficial effects of AT2R activation
were blocked by PPAR-c inhibition [87]. In high-fructose/
high-fat fed rats, compound 21 improved insulin sensitivity
and glucose tolerance comparably to the ARB, losartan.
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Moreover, compound 21 lowered triacylglyceride levels as
well, an effect not seen by losartan treatment [88]. Very
similar results were obtained in high-fat diet mice. In this
model, compound 21 improved insulin sensitivity, reduced
TNF-a, increased adiponectin and IL-10 levels, and
reduced serum triacylglyceride levels. Again, the effects of
AT2R stimulation were broader compared to the effects of
the ARB (valsartan in this study), which improved glucose
tolerance only. Notably, the effects of both compound 21
and valsartan seemed to be mediated via the AT2R as they
were not observed in AT2R-KO mice [89]. These results
are complemented by the in vitro data from 3T3-L1 adi-
pocytes. In this cell line, compound 21 reduced TNF-a-
induced IL-6 and MCP-1 expression, yet without activating
PPAR-c and without inducing adipocyte differentiation
[90]. Therefore, it remains controversial, whether PPAR-c
activation is involved in the signaling cascade of the
AT2R, at least in the cardio-metabolic area. The AT2R is
not only abundantly expressed in pancreatic b-cell of adult
rats, but its stimulation significantly improved insulin
synthesis and secretion [91]. Moreover, compound 21 up-
regulated superoxide dismutase expression, reduced
oxidative load and caspase-3 expression and consequently
prevented cell death of pancreatic b-cell in streptozotocin-
induced diabetic rats [92].
Several further data indicate that the attenuation of
inflammation and improvement of the metabolic profile by
AT2R stimulation translates into nephroprotective effects.
Such nephroprotective effects have previously been
reported in hypertensive models such as 2-kidney-1-clip
renovascular hypertension [93] or in stroke-prone SHR
[94]. The results on the protection against kidney damage
observed in diabetic animals are in line with these findings
in hypertensive models. In streptozotocin-induced diabetic
rats, compound 21 normalized TNF-a and IL-6 levels and
increased NO and cGMP with consequent attenuation of
urinary albumin to creatinine ratio, yet without affecting
blood pressure [95]. Similar protection against diabetic
nephropathy was recently reported, in type 1 diabetic mice,
in which compound 21 attenuated cystatin C levels, albu-
minuria, mesangial expansion, and glomerulosclerosis
[96]. Therefore, it seems that compound 21 prevents
albuminuria via normalization of the NO/cGMP pathway
but mainly via reduction of renal inflammatory infiltration
and subsequently the prevention structural alterations of
the glomerular filter.
Finally, AT2R stimulation exerted anti-inflammatory
and nephroprotective effects also in obese Zucker rats. In
these rats, the peptide AT2R agonist CGP-42112A reduced
systemic inflammation and oxidative load [97], and com-
pound 21 reduced TNF-a expression, renal macrophage
infiltration, fibrosis and albuminuria [98]. Although the
effects in Zucker rats were not associated with blood
pressure-lowering effect by AT2R stimulation, compound
21 prevented salt-sensitive hypertension in these rats. This
hemodynamic effect, not generally observed in other ani-
mal models, might be related to reduced renal Ang II and
AT1R and enhanced ACE2 and Ang (1–7) levels and
AT2R expression [99] or to the natriuretic effect by com-
pound 21, which might be unmasked under certain condi-
tions [100–102].
It has to be noted, that the AT2R pathway might be
stimulated by the Ang (1–7) produced by ACE2 as well.
Congruently, ACE2 overexpression improved fasting glu-
cose in diabetic mice [103] or vice-versa, the loss of ACE2
exaggerated high-calorie diet-induced insulin resistance
[104]. However, due to receptor hetero-dimerization, the
blockade of either AT2R or Mas receptor seems to block
the effects of the other receptor [105]. Thus, we need to be
cautious when attributing the effects of ACE2/Ang (1–7)
stimulation to the activation of a particular receptor (AT2R
or the Mas).
4 Combined Angiotensin Receptor Modulation
As described above, the RAS blockade currently represents
the gold standard in cardiovascular therapy, including
diabetic nephropathy. The mechanisms involved include
direct blockade of the deleterious effects of Ang II but also
indirect immune-modulatory effects. Similar mechanisms
are involved in the beneficial (e.g. anti-inflammatory,
insulin sensitizing, nephroprotective) effects of the stimu-
lation of the ‘‘protective RAS’’ in various animal models of
diabetes or obesity. Yet, because the mechanisms of AT2R
stimulation and AT1R blockade are only partly overlap-
ping as described above and display a certain comple-
mentarity, there might be a potential for the combination of
the AT1R blockade and AT2R stimulation (Fig. 1).
The idea of dual hit in the RAS is not novel. Some early
trials with surrogate end-points have investigated the
potential benefit of dual RAS blockade with variable out-
comes. In the CALM study in diabetic patients with
microalbuminuria, the ACE inhibitor ? ARB combination
led to more pronounced reduction of microalbuminuria
compared to either monotherapy [107], while no additive
effect on albuminuria was observed in high-risk patients in
the IMPROVE trial [108]. The combination of renin inhi-
bition and losartan significantly reduced proteinuria in the
AVOID study in diabetic patients with nephropathy [109,
110]. However, the results of the later studies with hard
end-points: ONTARGET [44, 111] and ALTITUDE [112]
advise against the use of dual RAS blockade. The
ONTARGET trial in high-risk patients displayed more
adverse events (such as hypotension, syncope, kidney
dysfunction, hyperkalemia) in the combined arm (the ACE
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inhibitor ramipril ? the ARB telmisartan). The ALTI-
TUDE trial, which tested the direct renin inhibitor, aliski-
ren, in diabetic patients with renal disease needed to be
halted prematurely due to increased incidence of adverse
events (slight numeric increase in stroke rates and signifi-
cant increase in hyperkalemia and hypotension) in the
aliskiren arm (on the background of ACE inhibition or
ARB treatment). As such, the concept of dual RAS
blockade failed primarily due to safety concerns. A recent
meta-analysis demonstrated that dual therapy was associ-
ated with 66 % higher risk of hypotension [113]. It was
hypothesized that lower blood pressure in the combination
arm might have contributed to the increased incidence of
renal end-points in the combination arm of the ONTAR-
GET trial [114] and that the low blood pressure at baseline
might be responsible for the renal dysfunction observed in
the aliskiren arm of the ALTITUDE trial [115]. These
considerations suggest that the second hit in the RAS
should not ‘‘knock-out’’ the RAS completely in order to
minimize the potential for undesired hypotension along
with other unwarranted effects. With this regard, the acti-
vation of the AT2R represents a putatively better suited
candidate for an add-on to the AT1R blocking strategies.
Yet, because these considerations represent a transla-
tional approach with a very specific aim, only few exper-
imental studies have investigated the effects of the
combination of AT1R blockade with AT2R stimulation.
Experiments in two animal models of hypertension
(L-NAME and SHR) indicate that there is no significant
additive blood pressure effect by AT2R stimulation when
added to the ARB (olmesartan or losartan, respectively)
[69, 70]. Nevertheless, a superior effect by the combination
treatment on some aspects of vascular remodeling (most
notably on hydroxyprolin/collagen content and arterial
stiffness) over monotherapy was observed [69, 70].
Therefore a clinical rationale for combined angiotensin
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Fig. 1 Renin–angiotensin system (RAS) and insulin sensitivity.
Scheme showing the modulation [by angiotensin AT2 receptor
(AT2R) agonist, angiotensin AT1 receptor AT1R blocker (ARB) or
angiotensin-converting enzyme (ACE) inhibition] of insulin sensitiv-
ity by the RAS and the involvement of pro-/anti-inflammatory signals.
The ACE converts angiotensin (Ang) I to Ang II. It also catalyses the
degradation of bradykinin (BK), which enhances the expression of
glucose transporter type 4 (GLUT4) [29], an effect opposed by AT1R
activation [28]. AT1R also disrupts insulin sensitivity by aldosterone-
mediated hypokalemia [65], vasoconstriction [5] and inhibition of
adipocyte (AC) differentiation [33]. On the other hand, the AT2R
promotes AC differentiation via prostacyclin (PGI2) production [106]
and inhibits NF-jB signaling via 11,12-epoxyeicosatrienoic acid
(EET) [80], with possible involvement of the peroxisome proliferator-
activated receptor-c (PPAR-c) [87] vs. [90]. PPAR-c activation
promotes adipocyte differentiation [88] the release of adiponectin
with its insulin sensitizing effects [63]
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receptor modulation includes the AT1R blockade aimed at
achieving target blood pressure values and the AT2R
stimulation aimed to reduce arterial stiffness in the long
term. Arterial stiffness is an independent predictor of car-
diovascular events and all-cause mortality [116]. The
reduction of arterial stiffness prevents the increase in the
systolic blood pressure, without compromising diastolic
blood pressure values (Fig. 2). Such a combined effect
might be of particular significance in end-stage renal
patients in which aortic stiffness attenuation has been
indeed shown to improve survival [117]. The mechanisms
responsible for these beneficial effects of the combined
angiotensin receptor blockade were largely attributed to
the anti-inflammatory effects of compound 21. In fact,
while the ARBs may also block the NF-jB activation, this
pathway might still be triggered independently from Ang
II. In contrast, stimulation of the AT2R might prevent
such NF-jB activation, with subsequent release of
adiponectin and the following insulin sensitizing effects
[80, 118].
At present, there is only one study which has investigated
the effects of combined AT2R stimulation ? AT1R block-
ade specifically in the setting of a metabolic disorder. In this
study, compound 21 was tested in comparison and in com-
binationwith losartan inZucker diabetic fatty rats.Add-on of
compound 21 extended the reduction of albuminuria from
15 weeks of age (in the losartan group) to 20 weeks of age
(the end of the experimental protocol). Moreover, while
losartan reduced renal macrophage infiltration, TNF-a
expression and glomerular and perivascular fibrosis, com-
pound 21 reduced tubulointerstitial fibrosis (the best corre-
late for renal disease progression) aswell. In the combination
arm, there was also a slight numeric tendency for larger
effect on glomerular and perivascular fibrosis compared to
losartan alone. Consistent with previous studies, reduced
triacylglyceride levels were observed only in groups treated
with compound 21. Finally, compound 21 neither alone, nor
in combination with losartan altered blood pressure, con-
firming that its beneficial effects are largely blood pressure-
independent [98]. Due to these additional beneficial effects
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Fig. 2 Combined angiotensin receptor modulation. Scheme showing
the rationale for combining the stimulation of the AT2 receptor
(AT2R) with the blockade of the angiotensin AT1 receptor AT1R by
the AT1R blockers (ARBs). The employment of the AT1R blockade
is aimed at achieving target blood pressure values and the AT2R
stimulation is aimed to reduce arterial stiffness in the long term. The
reduction of arterial stiffness prevents the increase in the systolic
blood pressure without compromising diastolic blood pressure values.
Such a combined effect might be of particular significance in the
elderly, in patients with isolated systolic hypertension or in end-stage
renal patients
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of the add-on AT2R stimulation to AT1R blockade, such
combination represents an interesting perspective for future
clinical investigation.
5 Conclusion
The combined modulation of angiotensin receptors by
AT1R blockade and simultaneous AT2R stimulation pro-
vides an intriguing novel therapeutic concept. This
approach might be suitable in particular for patient popu-
lations with well-controlled blood pressure or where further
blood pressure reduction is not desired. In addition,
patients with chronic low-grade inflammation and/or iso-
lated systolic hypertension might benefit from the anti-in-
flammatory and de-stiffening effects of the AT2R
stimulation additive to the AT1R blockade. Yet, there are
no clinical and only sparse pre-clinical in vivo data avail-
able for this approach. Thus, future studies on the com-
bined angiotensin receptor modulation in the field of
cardio-metabolic diseases represent an attractive and
highly sought endeavor.
Compliance with Ethical Standards
Funding The work was supported by the Grants of the Scientific
Grant Agency VEGA 1-0380-14 and Agency for Science and
Research Support APVV 0205-11.
Conflicts of interest Ludovit Paulis, Sebastien Foulquier, Pawel
Namsolleck, Chaira Ricarti and Thomas Unger have no potential
conflicts of interest that might be relevant to the contents of this
review. Ulrike Steckelings has received short term student fellowship
Grant and free drug supply of compound 21 (for research work) from
Vicore Pharma.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren
M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C,
Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz
S, Mezzani A, Prescott E, Ryden L, Scherer M, Syva¨nne M,
Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL,
Zannad F, European Association for Cardiovascular Prevention
and Rehabilitation (EACPR), ESC Committee for Practice
Guidelines (CPG). European guidelines on cardiovascular dis-
ease prevention in clinical practice (version 2012). The Fifth
Joint Task Force of the European Society of Cardiology and
Other Societies on Cardiovascular Disease Prevention in
Clinical Practice (constituted by representatives of nine societies
and by invited experts). Eur Heart J. 2012;33(13):1635–701.
2. Magliano DJ, Shaw JE, Zimmet PZ. How to best define the
metabolic syndrome. Ann Med. 2006;38:34–41.
3. World Heath Organization. Fact sheet: Obesity and overweight.
2007. http://www.who.int/dietphysical-activity/publications/
facts/obesity/en/. Accessed 8 June 2007.
4. Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KM.
Estimated number of adults with prediabetes in the US in 2000:
opportunities for prevention. Diabetes Care. 2003;26:645–9.
5. Julius S, Gudbrandsson T, Jamerson K, Tariq Shahab S,
Andersson O. The hemodynamic link between insulin resistance
and hypertension. J Hypertens. 1991;9(11):983–6.
6. Katovich MJ, Pachori A. Effects of inhibition of the renin–an-
giotensin system on the cardiovascular actions of insulin. Dia-
betes Obes Metab. 2000;2(1):3–14.
7. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin
resistance. Annu Rev Physiol. 2010;72:219–46.
8. Hotamisligil GS. Inflammation and metabolic disorders. Nature.
2006;444(7121):860–7.
9. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB.
Elevated C-reactive protein levels in overweight and obese
adults. JAMA. 1999;282(22):2131–5.
10. Fried SK, Bunkin DA, Greenberg AS. Omental and subcuta-
neous adipose tissues of obese subjects release interleukin-6:
depot difference and regulation by glucocorticoid. J Clin
Endocrinol Metab. 1998;83(3):847–50.
11. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M,
Marfella R, Giugliano D. Effect of weight loss and lifestyle
changes on vascular inflammatory markers in obese women: a
randomized trial. JAMA. 2003;289(14):1799–804.
12. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A,
Lee J, Goldfine AB, Benoist C, Shoelson S, Mathis D. Lean, but
not obese, fat is enriched for a unique population of regulatory T
cells that affect metabolic parameters. Nat Med.
2009;15(8):930–9.
13. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D,
Morel CR, Goforth MH, Subramanian V, Mukundan L, Ferrante
AW, Chawla A. Alternative M2 activation of Kupffer cells by
PPARdelta ameliorates obesity-induced insulin resistance. Cell
Metab. 2008;7(6):496–507.
14. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in
inflammation and metabolic disease. Nat Rev Immunol.
2011;11(2):85–97.
15. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced gly-
cation end products (RAGE)-mediated neurite outgrowth and
activation of NF-kappaB require the cytoplasmic domain of the
receptor but different downstream signaling pathways. J Biol
Chem. 1999;274(28):19919–24.
16. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H,
Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, Yoshimura K,
Kadowaki T, Nagai R. CD8? effector T cells contribute to
macrophage recruitment and adipose tissue inflammation in
obesity. Nat Med. 2009;15(8):914–20.
17. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S,
Vaddi K, Charo I, Leibel RL, Ferrante AW Jr. CCR2 modulates
inflammatory and metabolic effects of high-fat feeding. J Clin
Invest. 2006;116(1):115–24.
18. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR,
Lechler RI. Leptin modulates the T-cell immune response and
reverses starvation-induced immunosuppression. Nature.
1998;394(6696):897–901.
19. Santos-Alvarez J, Goberna R, Sa´nchez-Margalet V. Human
leptin stimulates proliferation and activation of human circu-
lating monocytes. Cell Immunol. 1999;194(1):6–11.
8 L. Paulis et al.
20. Friedman JM, Halaas JL. Leptin and the regulation of body
weight in mammals. Nature. 1998;395(6704):763–70.
21. Ogawa S, Lozach J, Jepsen K, Sawka-Verhelle D, Perissi V,
Sasik R, Rose DW, Johnson RS, Rosenfeld MG, Glass CK. A
nuclear receptor corepressor transcriptional checkpoint control-
ling activator protein 1-dependent gene networks required for
macrophage activation. Proc Natl Acad Sci USA.
2004;101(40):14461–6.
22. Huang W, Ghisletti S, Perissi V, Rosenfeld MG, Glass CK.
Transcriptional integration of TLR2 and TLR4 signaling at the
NCoR depression checkpoint. Mol Cell. 2009;35:48–57.
23. Karlsson C, Lindell K, Ottosson M, Sjo¨stro¨m L, Carlsson B,
Carlsson LM. Human adipose tissue expresses angiotensinogen
and enzymes required for its conversion to angiotensin II. J Clin
Endocrinol Metab. 1998;83(11):3925–9.
24. Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Kral
JG. Distribution of angiotensin II receptors in rat and human
adipocytes. J Lipid Res. 1994;35(8):1378–85.
25. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J,
Ailhaud G, Teboul M, Massie´ra F, Sharma AM. The adipose-
tissue renin–angiotensin-aldosterone system: role in the meta-
bolic syndrome? Int J Biochem Cell Biol. 2003;35(6):807–25.
26. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T.
International union of pharmacology. XXIII. The angiotensin II
receptors. Pharmacol Rev. 2000;52(3):415–72.
27. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide
diuretics, potassium, and the development of diabetes: a quan-
titative review. Hypertension. 2006;48(2):219–24.
28. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M,
Cui TX, Horiuchi M. Angiotensin II type-1 receptor blocker
valsartan enhances insulin sensitivity in skeletal muscles of
diabetic mice. Hypertension. 2004;43(5):1003–10.
29. Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y,
Iwai M, Horiuchi M. ACE inhibitor improves insulin resistance
in diabetic mouse via bradykinin and NO. Hypertension.
2002;40(3):329–34.
30. Jones BH, Standridge MK, Moustaid N. Angiotensin II increases
lipogenesis in 3T3-L1 and human adipose cells. Endocrinology.
1997;138(4):1512–9.
31. Wakil SJ, Stoops JK, Joshi VC. Fatty acid synthesis and its
regulation. Annu Rev Biochem. 1983;52:537–79.
32. Weisinger RS, Begg DP, Chen N, Jois M, Mathai ML, Sinclair
AJ. The problem of obesity: is there a role for antagonists of the
renin–angiotensin system? Asia Pac J Clin Nutr. 2007;16(Suppl
1):359–67.
33. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature
adipocytes inhibit in vitro differentiation of human pre-
adipocytes via angiotensin type 1 receptors. Diabetes.
2002;51(6):1699–707.
34. Dagenais NJ, Jamali F. Protective effects of angiotensin II
interruption: evidence for antiinflammatory actions Pharma-
cotherapy. 2005;25:1213–29.
35. Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory
mediator. Curr Opin Investig Drugs. 2002;3(4):569–77.
36. Ma LJ, Corsa BA, Zhou J, Yang H, Li H, Tang YW, Babaev
VR, Major AS, Linton MF, Fazio S, Hunley TE, Kon V, Fogo
AB. Angiotensin type 1 receptor modulates macrophage polar-
ization and renal injury in obesity. Am J Physiol Renal Physiol.
2011;300(5):F1203–13.
37. The SOLVD Investigators. Effect of enalapril on survival in
patients with reduced left ventricular ejection fractions and
congestive heart failure. N Engl J Med. 1991;325(5):293–302.
38. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T,
Niklason A, Luomanma¨ki K, Dahlo¨f B, de Faire U, Mo¨rlin C,
Karlberg BE, Wester PO, Bjo¨rck JE. Effect of angiotensin-
converting-enzyme inhibition compared with conventional
therapy on cardiovascular morbidity and mortality in hyperten-
sion: the Captopril Prevention Project (CAPP) randomised trial.
Lancet. 1999;353:611–6.
39. Hansson L, Lindholm LH, Ekbom T, Dahlo¨f B, Lanke J, Sch-
erste´n B, Wester PO, Hedner T, de Faire U. Randomised trial of
old and new antihypertensive drugs in elderly patients: cardio-
vascular mortality and morbidity the Swedish Trial in Old
Patients with Hypertension-2 study. Lancet. 1999;354:1751–6.
40. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril,
on cardiovascular events in high-risk patients. The Heart Out-
comes Prevention Evaluation Study Investigators. N Engl J
Med. 2000;342(3):145–53.
41. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ,
Michelson EL, Olofsson B, Ostergren J, Yusuf S. Pocock S;
CHARMInvestigators andCommittees. Effects of candesartan on
mortality and morbidity in patients with chronic heart failure: the
CHARM-Overall programme. Lancet. 2003;362(9386):759–66.
42. Dahlo¨f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de
Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Ped-
ersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S,
Wedel H, LIFE Study Group. Cardiovascular morbidity and
mortality in the Losartan Intervention For Endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol.
Lancet. 2000;359:995–1003.
43. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S,
Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F,
Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes
in hypertensive patients at high cardiovascular risk treated with
regimens based on valsartan or amlodipine: the VALUE ran-
domised trial. Lancet. 2004;363(9426):2022–31.
44. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L,
Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.
Telmisartan, ramipril, or both in patients at high risk for vascular
events. N Engl J Med. 2008;358:1547–59.
45. Dahlo¨f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de
Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Ped-
ersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S,
Wedel H, LIFE Study Group. Cardiovascular morbidity and
mortality in the Losartan Intervention For Endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol.
Lancet. 2002;359(9311):995–1003.
46. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of
antihypertensive drugs: a network meta-analysis. Lancet.
2007;369(9557):201–7.
47. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of
angiotensin-converting-enzyme inhibition on diabetic
nephropathy. The Collaborative Study Group. N Engl J Med.
1993;329(20):1456–62.
48. Parving HH, Lehnert H, Bro¨chner-Mortensen J, Gomis R,
Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes
and Microalbuminuria Study Group. The effect of irbesartan on
the development of diabetic nephropathy in patients with type 2
diabetes. N Engl J Med. 2001;345(12):870–8.
49. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE,
Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S,
RENAAL Study Investigators. Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and
nephropathy. N Engl J Med. 2001;345(12):861–9.
50. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis
JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study
Group. Renoprotective effect of the angiotensin-receptor
antagonist irbesartan in patients with nephropathy due to type 2
diabetes. N Engl J Med. 2001;345(12):851–60.
51. Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T,
Porta M, Parving HH. Effect of candesartan on
Combined Angiotensin Receptor Modulation 9
microalbuminuria and albumin excretion rate in diabetes: three
randomized trials. Ann Intern Med. 2009;151(1):11–20, W3–4.
52. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne
J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC,
Viberti G, ROADMAP Trial Investigators. Olmesartan for the
delay or prevention of microalbuminuria in type 2 diabetes.
N Engl J Med. 2011;364(10):907–17.
53. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z,
Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
Proteinuria, a target for renoprotection in patients with type 2
diabetic nephropathy: lessons from RENAAL. Kidney Int.
2004;65(6):2309–20.
54. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper
ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner
BM, de Zeeuw D. Albuminuria is a target for renoprotective
therapy independent from blood pressure in patients with type 2
diabetic nephropathy: post hoc analysis from the Reduction of
Endpoints in NIDDM with the Angiotensin II Antagonist
Losartan (RENAAL) trial. J Am Soc Nephrol.
2007;18(5):1540–6.
55. Kurtz TW, Klein U. Next generation multifunctional angiotensin
receptor blockers. Hypertens Res. 2009;32(10):826–34.
56. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angio-
tensin type 1 receptor blockers induce peroxisome proliferator-
activated receptor-gamma activity. Circulation. 2004;109(17):
2054–7.
57. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S,
Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular
characterization of new selective peroxisome proliferator-acti-
vated receptor gamma modulators with angiotensin receptor
blocking activity. Diabetes. 2005;54(12):3442–52.
58. Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T,
Kintscher U. Regulation of peroxisome proliferator-activated
receptor gamma activity by losartan metabolites. Hypertension.
2006;47(3):586–9.
59. Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A,
Bo¨hm C, Hartge M, Gust R, Staels B, Unger T, Kintscher U.
Liver-specific peroxisome proliferator-activated receptor alpha
target gene regulation by the angiotensin type 1 receptor blocker
telmisartan. Diabetes. 2008;57(5):1405–13.
60. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P,
Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identifica-
tion of telmisartan as a unique angiotensin II receptor antagonist
with selective PPARgamma-modulating activity. Hypertension.
2004;43(5):993–1002.
61. Kappert K, Tsuprykov O, Kaufmann J, Fritzsche J, Ott I, Goebel
M, Ba¨hr IN, Ha¨ssle PL, Gust R, Fleck E, Unger T, Stawowy P,
Kintscher U. Chronic treatment with losartan results in sufficient
serum levels of the metabolite EXP3179 for PPARgamma
activation. Hypertension. 2009;54(4):738–43.
62. Ba¨hr IN, Tretter P, Kru¨ger J, Stark RG, Schimkus J, Unger T,
Kappert K, Scholze J, Parhofer KG, Kintscher U. High-dose
treatment with telmisartan induces monocytic peroxisome pro-
liferator-activated receptor-c target genes in patients with the
metabolic syndrome. Hypertension. 2011;58(4):725–32.
63. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M,
Krikov M, Tho¨ne-Reineke C, Unger T, Kintscher U. PPAR-
gamma-activating angiotensin type-1 receptor blockers induce
adiponectin. Hypertension. 2005;46(1):137–43.
64. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona
R, SullivanME,DoleW,Rutledge JC.Angiotensin II is associated
with activation of NF-kappaB-mediated genes and downregula-
tion of PPARs. Physiol Genomics. 2002;11(1):21–30.
65. Kintscher U, Foryst-Ludwig A, Unger T. Inhibiting angiotensin
type 1 receptors as a target for diabetes. Expert Opin Ther
Targets. 2008;12(10):1257–63.
66. Paulis L, Rajkovicova R, Simko F. New developments in the
pharmacological treatment of hypertension: dead-end or a
glimmer at the horizon? Curr Hypertens Rep. 2015;17(6):557.
67. Danyel LA, Schmerler P, Paulis L, Unger T, Steckelings UM.
Impact of AT2-receptor stimulation on vascular biology, kidney
function, and blood pressure. Integr Blood Press Control.
2013;6:153–61.
68. Unger T, Steckelings UM, dos Santos RAS. The protective arm
of the renin angiotensin system. Functional aspects and thera-
peutic implications. ISBN 978-0-12-801364-9 1st ed. Elsevier:
Academic Press; 2015.
69. Paulis L, Becker ST, Lucht K, Schwengel K, Slavic S, Kaschina
E, Tho¨ne-Reineke C, Dahlo¨f B, Baulmann J, Unger T, Stecke-
lings UM. Direct angiotensin II type 2 receptor stimulation in
Nx-nitro-L-arginine-methyl ester-induced hypertension: the
effect on pulse wave velocity and aortic remodeling. Hyper-
tension. 2012;59(2):485–92.
70. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P,
Schiffrin EL. Angiotensin type 2 receptor agonist compound 21
reduces vascular injury and myocardial fibrosis in stroke-prone
spontaneously hypertensive rats. Hypertension. 2012;59(2):485–92.
71. Min LJ, Mogi M, Tsukuda K, Jing F, Ohshima K, Nakaoka H,
Kan-No H, Wang XL, Chisaka T, Bai HY, Iwanami J, Horiuchi
M. Direct stimulation of angiotensin II type 2 receptor initiated
after stroke ameliorates ischemic brain damage. Am J Hyper-
tens. 2014;27(8):1036–44.
72. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M,
Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck
P, Tscho¨pe C, Hallberg A, Alterman M, Hucko T, Paetsch I,
Dietrich T, Schnackenburg B, Graf K, Dahlo¨f B, Kintscher U,
Unger T, Steckelings UM. Angiotensin II type 2 receptor
stimulation: a novel option of therapeutic interference with the
renin–angiotensin system in myocardial infarction? Circulation.
2008;118(24):2523–32.
73. Lauer D, Slavic S, Sommerfeld M, Tho¨ne-Reineke C, Shar-
kovska Y, Hallberg A, Dahlo¨f B, Kintscher U, Unger T,
Steckelings UM, Kaschina E. Angiotensin type 2 receptor
stimulation ameliorates left ventricular fibrosis and dysfunction
via regulation of tissue inhibitor of matrix metalloproteinase
1/matrix metalloproteinase 9 axis and transforming growth
factor b1 in the rat heart. Hypertension. 2014;63(3):e60–7.
74. Brouwers S, Smolders I, Wainford RD, Dupont AG. Hypoten-
sive and sympathoinhibitory responses to selective central AT2
receptor stimulation in spontaneously hypertensive rats. Clin Sci
(Lond). 2015;129:81–92.
75. Gao J, Zucker IH, Gao L. Activation of central angiotensin type
2 receptors by compound 21 improves arterial baroreflex sen-
sitivity in rats with heart failure. Am J Hypertens.
2014;27(10):1248–56.
76. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases
aortic cyclic GMP in SHRSP by a kinin-dependent mechanism.
Hypertension. 1998;31(1 Pt 2):349–55.
77. Dandapat A, Hu CP, Chen J, Liu Y, Khan JA, Remeo F, et al.
Over-expression of angiotensin II type 2 receptor (agtr2)
decreases collagen accumulation in atherosclerotic plaque.
Biochem Biophys Res Commun. 2008;366:871–7.
78. Fischer TA, Singh K, O’Hara DS, Kaye DM, Kelly RA. Role of
AT1 and AT2 receptors in regulation of MAPKs and MKP-1 by
ANG II in adult cardiac myocytes. Am J Physiol. 1998;275(3 Pt
2):H906–16.
79. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U. The
angiotensin II AT2 receptor is an AT1 receptor antagonist.
J Biol Chem. 2001;276(43):39721–6.
80. Rompe F, Artuc M, Hallberg A, Alterman M, Stro¨der K, Tho¨ne-
Reineke C, Reichenbach A, Schacherl J, Dahlo¨f B, Bader M,
Alenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H,
10 L. Paulis et al.
Schmidt C, Schunck WH, Unger T, Steckelings UM. Direct
angiotensin II type 2 receptor stimulation acts anti-inflammatory
through epoxyeicosatrienoic acid and inhibition of nuclear fac-
tor kappaB. Hypertension. 2010;55(4):924–31.
81. Valero-Esquitino V, Lucht K, Namsolleck P, Monnet-Tschudi F,
Stubbe T, Lucht F, Liu M, Ebner F, Brandt C, Danyel LA,
Villela DC, Paulis L, Thoene-Reineke C, Dahlo¨f B, Hallberg A,
Unger T, Sumners C, Steckelings UM. Direct angiotensin type 2
receptor (AT2R) stimulation attenuates T-cell and microglia
activation and prevents demyelination in experimental autoim-
mune encephalomyelitis in mice. Clin Sci (Lond).
2015;128(2):95–109.
82. Dhande I, Ma W, Hussain T. Angiotensin AT2 receptor stimu-
lation is anti-inflammatory in lipopolysaccharide-activated THP-
1 macrophages via increased interleukin-10 production. Hyper-
tens Res. 2015;38(1):21–9.
83. Menk M, Graw JA, von Haefen C, Sifringer M, Schwaiberger D,
Unger T, Steckelings U, Spies CD. Stimulation of the angio-
tensin II AT2 receptor is anti-inflammatory in human
lipopolysaccharide-activated monocytic cells. Inflammation.
2015 [Epub ahead of print].
84. Sampson AK, Irvine JC, Shihata WA, Dragoljevic D, Lumsden
N, Huet O, Barnes T, Unger T, Steckelings UM, Jennings GL,
Widdop RE, Chin-Dusting JP. Compound 21 prevents
endothelial inflammation and leukocyte adhesion in vitro and
in vivo. Br J Pharmacol. 2015. doi:10.1111/bph.13063.
85. Miura S, Matsuo Y, Kiya Y, Karnik SS, Saku K. Molecular
mechanisms of the antagonistic action between AT1 and AT2
receptors. Biochem Biophys Res Commun. 2010;391(1):85–90.
86. Mogi M, Iwai M, Horiuchi M. New insights into the regulation
of angiotensin receptors. Curr Opin Nephrol Hypertens.
2009;18(2):138–43.
87. Oshima K, Mogi M, Jing F, Iwanami J, Tsukuda K, Min LJ,
Ogimoto A, Dahlo¨f B, Steckelings UM, Unger T, Higaki J,
Horiuchi M. Direct angiotensin II type 2 receptor stimulation
ameliorates insulin resistance in type 2 diabetes mice with
PPARc activation. PLoS One. 2012;7(11):e48387.
88. Shum M, Pinard S, Guimond MO, Labbe´ SM, Roberge C,
Baillargeon JP, Langlois MF, Alterman M, Wallinder C, Hall-
berg A, Carpentier AC, Gallo-Payet N. Angiotensin II type 2
receptor promotes adipocyte differentiation and restores adipo-
cyte size in high-fat/high-fructose diet-induced insulin resistance
in rats. Am J Physiol Endocrinol Metab. 2013;304(2):E197–210.
89. Wardat S, Iwai M, Horiuchi M, Dahlo¨f B, Hallberg A, Unger T,
Kintscher U, Steckelings UM, Foryst-Ludwig. A glucose toler-
ance and insulin sensitivity is improved in obese mice by direct
stimulation of angiotensin AT2-receptors, 16th annual meeting
of the european council for cardiovascular research (ECCR)
30.9-2.10 2011 La Colle sur Loup, Nice, France.
90. Wardat S, Kintscher U, Steckelings UM, Foryst-Ludwig A.
TNF-a-mediated inflammatory response in adipocytes is atten-
uated by the direct activation of angiotensin II AT2-receptors.
Hypertension. 2009;54(5):1179.
91. Shao C, Zucker IH, Gao L. Angiotensin type 2 receptor in
pancreatic islets of adult rats: a novel insulinotropic mediator.
Am J Physiol Endocrinol Metab. 2013;305(10):E1281–91.
92. Shao C, Yu L, Gao L. Activation of angiotensin type 2 receptors
partially ameliorates streptozotocin-induced diabetes in male
rats by islet protection. Endocrinology. 2014;155(3):793–804.
93. Matavelli LC, Huang J, Siragy HM. Angiotensin AT2 receptor
stimulation inhibits early renal inflammation in renovascular
hypertension. Hypertension. 2011;57(2):308–13.
94. Gelosa P, Pignieri A, Fa¨ndriks L, de Gasparo M, Hallberg A,
Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E, Sironi
L. Stimulation of AT2 receptor exerts beneficial effects in
stroke-prone rats: focus on renal damage. J Hypertens.
2009;27(12):2444–51.
95. Matavelli LC, Zatz R, Siragy HM. A nonpeptide angiotensin II
type 2 receptor agonist prevents renal inflammation in early
diabetes. J Cardiovasc Pharmacol. 2015;65(4):371–6.
96. Koulis C, Chow BS, McKelvey M, Steckelings UM, Unger T,
Thallas-Bonke V, Thomas MC, Cooper ME, Jandeleit-Dahm
KA, Allen TJ. AT2R agonist, compound 21, is reno-protective
against type 1 diabetic nephropathy. Hypertension.
2015;65(5):1073–81.
97. Sabuhi R1, Ali Q, Asghar M, Al-Zamily NR, Hussain T. Role of
the angiotensin II AT2 receptor in inflammation and oxidative
stress: opposing effects in lean and obese Zucker rats. Am J
Physiol Renal Physiol. 2011;300(3):F700–6.
98. Castoldi G, di Gioia CR, Bombardi C, Maestroni S, Carletti R,
Steckelings UM, Dahlo¨f B, Unger T, Zerbini G, Stella A.
Prevention of diabetic nephropathy by compound 21, selective
agonist of angiotensin type 2 receptors, in Zucker diabetic fatty
rats. Am J Physiol Renal Physiol. 2014;307:F1123–31.
99. Ali Q, Patel SN, Hussain T. Angiotensin AT2 receptor agonist
prevents salt-sensitive hypertension in obese Zucker rats. Am J
Physiol Renal Physiol. 2015. doi:10.1152/ajprenal.00002.2015.
100. Brouwers S, Smolders I, Massie A, Dupont AG. Angiotensin II
type 2 receptor-mediated and nitric oxide-dependent renal
vasodilator response to compound 21 unmasked by angiotensin-
converting enzyme inhibition in spontaneously hypertensive rats
in vivo. Hypertension. 2013;62:920–6.
101. Hilliard LM, Chow CL, Mirabito KM, Steckelings UM, Unger
T, Widdop RE, Denton KM. Angiotensin type 2 receptor stim-
ulation increases renal function in female, but not male, spon-
taneously hypertensive rats. Hypertension. 2014;64(2):378–83.
102. Kemp BA, Howell NL, Gildea JJ, Keller SR, Padia SH, Carey
RM. AT2 receptor activation induces natriuresis and lowers
blood pressure. Circ Res. 2014;115(3):388–99.
103. Bindom SM, Hans CP, Xia H, Boulares AH, Lazartigues E.
Angiotensin I-converting enzyme type 2 (ACE2) gene therapy
improves glycemic control in diabetic mice. Diabetes.
2010;59(10):2540–8.
104. Takeda M, Yamamoto K, Takemura Y, Takeshita H, Hongyo K,
Kawai T, Hanasaki-Yamamoto H, Oguro R, Takami Y, Tatara
Y, Takeya Y, Sugimoto K, Kamide K, Ohishi M, Rakugi H.
Loss of ACE2 exaggerates high-calorie diet-induced insulin
resistance by reduction of GLUT4 in mice. Diabetes.
2013;62(1):223–33.
105. Villela D, Leonhardt J, Patel N, Joseph J, Kirsch S, Hallberg A,
Unger T, Bader M, Santos RA, Sumners C, Steckelings UM.
Angiotensin type 2 receptor (AT2R) and receptor Mas: a com-
plex liaison. Clin Sci (Lond). 2015;128(4):227–34.
106. Ne´grel R, Gaillard D, Ailhaud G. Prostacyclin as a potent
effector of adipose-cell differentiation. Biochem J.
1989;257(2):399–405.
107. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R,
Watts RW, Cooper ME. Randomised controlled trial of dual
blockade of renin–angiotensin system in patients with hyper-
tension, microalbuminuria, and non-insulin dependent diabetes:
the candesartan and lisinopril microalbuminuria (CALM) study.
BMJ. 2000;321(7274):1440–4.
108. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de
Champlain J, Weber MA, Raz I. Treatment of microalbuminuria
in hypertensive subjects with elevated cardiovascular risk:
results of the IMPROVE trial. Kidney Int. 2007;72(7):879–85.
109. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK,
AVOID Study Investigators. Aliskiren combined with losartan
in type 2 diabetes and nephropathy. N Engl J Med.
2008;358(23):2433–46.
Combined Angiotensin Receptor Modulation 11
110. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK,
Parving HH. Aliskiren in combination with losartan reduces
albuminuria independent of baseline blood pressure in patients
with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol.
2011;6(5):1025–31.
111. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H,
Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S,
Dickstein K, Keltai M, Metsa¨rinne K, Oto A, Parkhomenko A,
Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET
investigators. Renal outcomes with telmisartan, ramipril, or
both, in people at high vascular risk (the ONTARGET study): a
multicentre, randomised, double-blind, controlled trial. Lancet.
2008;372(9638):547–53.
112. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner
SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nico-
laides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTI-
TUDE Investigators. Cardiorenal end points in a trial of
aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):
2204–13.
113. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH.
Efficacy and safety of dual blockade of the renin–angiotensin
system: meta-analysis of randomised trials. BMJ. 2013;346:
f360.
114. Volpe M, Danser AH, Menard J, Waeber B, Mueller DN,
Maggioni AP, Ruilope LM. Inhibition of the renin–angiotensin-
aldosterone system: is there room for dual blockade in the car-
diorenal continuum? J Hypertens. 2012;30(4):647–54.
115. de Boer RA, Azizi M, Danser AJ, Nguyen G, Nussberger J,
Ruilope LM, Schmieder RE, Volpe M. Dual RAAS suppression:
recent developments and implications in light of the ALTI-
TUDE study. J Renin Angiotensin Aldosterone Syst.
2012;13(3):409–12.
116. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of
cardiovascular events and all-cause mortality with arterial
stiffness: a systematic review and meta-analysis. J Am Coll
Cardiol. 2010;55:1318–27.
117. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME,
London GM. Impact of aortic stiffness attenuation on survival of
patients in end-stage renal failure. Circulation. 2001;103:
987–92.
118. Sodhi K, Inoue K, Gotlinger KH, Canestraro M, Vanella L, Kim
DH, Manthati VL, Koduru SR, Falck JR, Schwartzman ML,
Abraham NG. Epoxyeicosatrienoic acid agonist rescues the
metabolic syndrome phenotype of HO-2-null mice. J Pharmacol
Exp Ther. 2009;331(3):906–16.
12 L. Paulis et al.
